Abstract
For decades, experts have endorsed the inclusion of low-dose aminoglycosides (AGs) in initial treatment for patients with Staphylococcus aureus bacteremia, especially when endocarditis is suspected. This practice made sense in light of strong in vitro evidence of antibiotic synergy and clinical data that showed that bacteremias cleared faster with two drugs; …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have